Alcentra Capital Corporation (NasdaqGS:ABDC) announced that its Board of Directors has entered into a formal review process to evaluate strategic alternatives for the Company. The Board of Directors has authorized its Committee of Independent Directors to lead the process. The Committee of Independent Directors has engaged Houlihan Lokey, Inc. as its financial advisor.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
133.1 USD | -0.18% | -1.97% | +10.66% |
05-14 | UBS Adjusts Houlihan Lokey Price Target to $145 From $157, Maintains Buy Rating | MT |
05-09 | BGSF Posts Lower Q1 Results, Starts Strategic Review, Suspends Dividend; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+10.66% | 9.21B | |
-7.07% | 36.33B | |
-9.50% | 12.75B | |
+5.51% | 9.21B | |
+0.02% | 3.96B | |
+20.77% | 3.31B | |
+2.49% | 3.09B | |
+1.51% | 2.84B | |
-1.86% | 2.39B | |
+10.36% | 956M |
- Stock Market
- Equities
- HLI Stock
- News Houlihan Lokey, Inc.
- Alcentra Capital Corporation Announces Strategic Alternatives Review